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Inhibition of NEDD8-activating enzyme (NAE) has
emerged as a highly promising approach to treat
cancer through the adenosine sulfamate analog
MLN4924. Here, we show that selective pressure
results in HCT116 colorectal carcinoma cells with
decreased MLN4924 sensitivity and identify a
single-nucleotide transition that changes alanine
171 to threonine (A171T) of the NAE subunit UBA3.
This reduces the enzyme’s affinity for MLN4924
and ATP while increasing NEDD8 activation at phys-
iological ATP concentrations. Expression of UBA3
A171T is sufficient to decrease MLN4924 sensitivity
of naive HCT116 cells, indicating that it is a dominant
suppressor of MLN4924-mediated cell death. Our
data suggest that the on-target potency of
MLN4924 selects for a point mutation in NAE that
overcomes the molecule’s inhibitory effects, allow-
ing cancer cell survival.INTRODUCTION
The modification of cullin proteins with NEDD8 (neddylation)
regulates the activity of cullin-RING ubiquitin ligases (CRLs)
(Bosu andKipreos, 2008; Pan et al., 2004; Petroski andDeshaies,
2005). Similar to all ubiquitin-like proteins, NEDD8 conjugation
relies on an enzymatic cascade involving initial ATP-dependent
activation prior to covalent NEDD8 transfer onto substrates
(Bohnsack and Haas, 2003; Schulman and Harper, 2009).
NEDD8-activating enzyme (NAE) consists of NAE1 (ULA1,
APPBP1) and UBA3 (UBE1C), with the latter containing the ATP
binding pocket and catalytic cysteine (Gong and Yeh, 1999;
Osaka et al., 1998). Neddylation of CRLs triggers structural rear-
rangements associated with enhanced ubiquitin modification of
CRL-bound protein substrates (Duda et al., 2008; Osaka et al.,
2000; Podust et al., 2000; Read et al., 2000; Saha and Deshaies,
2008). Because cullin neddylation is reversible through the COP9
signalosome (CSN) (Cope et al., 2002; Lyapina et al., 2001), this
functions as a highly dynamic mechanism for regulating ubiqui-
tin- and proteasome-dependent protein homeostasis by CRLs.
The anticancer effects of the FDA-approved proteasome
inhibitor bortezomib (Velcade) have motivated efforts to developother molecules that target cellular protein homeostasis mecha-
nisms such as the NAE inhibitor MLN4924 (Cohen and Tcherpa-
kov, 2010; Kane et al., 2003, 2007; Nalepa et al., 2006; Petroski,
2008; Soucy et al., 2009). MLN4924 rapidly eliminates CRL ned-
dylation, leading to CRL substrate accumulation and DNA rere-
plication prior to cancer cell apoptosis (Soucy et al., 2009).
This molecule potently inhibits tumor growth in mouse xenograft
studies and appears well tolerated at different doses and treat-
ment regimens (Soucy et al., 2009). These promising preclinical
studies have motivated phase I and phase I/II clinical trials for
hematologic and advanced nonhematologic cancers as well as
efforts to develop similar inhibitors for other ubiquitin and ubiqui-
tin-like protein-activating enzymes (E1s) (Brownell et al., 2010;
Chen et al., 2011; Milhollen et al., 2010, 2011; Soucy et al.,
2009; Swords et al., 2010).
MLN4924 is an adenosine sulfamate analog that relies on the
NAE catalytic cycle to generate the inhibitory NEDD8-MLN4924
covalent adduct in situ (Brownell et al., 2010). This adduct resem-
bles the acyl adenylate intermediate formedbetweenNEDD8and
AMP during NEDD8 activation and functions as a tight binding
inhibitor that prevents subsequent ATP and NEDD8 binding
(Brownell et al., 2010; Petroski, 2010). Although E1s have con-
servedcatalytic activities and highdegreesof sequence similarity
(Schulman and Harper, 2009), MLN4924 has remarkable on-
target selectivity because it is 300- and 1,500-fold more potent
against NAE than the E1s for SUMO and ubiquitin, respectively
(Brownell et al., 2010; Soucy et al., 2009). In contrast, another
adenosine sulfamate analog, Compound 1, functions as a nonse-
lective substrate-assisted inhibitor of canonical E1s despite
structural features similar to MLN4924 (Brownell et al., 2010;
Chen et al., 2011). Thus, these adenosine sulfamate analogs
may be fine-tuned toward selectively inhibiting a specific E1. It
remains a highly significant challenge, however, to understand
the complex mechanism of action of these molecules and to
determine what underlies E1 selectivity and sensitivity. Here, we
show that HCT116 colorectal carcinoma cells develop resistance
to MLN4924-induced apoptosis and identify a mutation in a
previously uncharacterized residue of UBA3 that provides a
dominant and transferable decrease in MLN4924 sensitivity.
RESULTS
HCT116 Cells Develop MLN4924 Resistance
Although HCT116 colorectal carcinoma cells transiently treated
with MLN4924 undergo DNA rereplication and cell deathCell Reports 1, 309–316, April 19, 2012 ª2012 The Authors 309
Figure 1. HCT116 Cells Lose Sensitivity to the NAE Inhibitor MLN4924 upon Prolonged Exposure and Serial Culturing
(A–C) Growth of HCT116 cells (HMS versus HMR cells) in the presence or absence of 3 mMMLN4924 (A). The viability of HMS and HMR cells treated for 48 hr with
MLN4924 (B) or bortezomib (C) was assessed by quantifying cellular ATP levels. Error bars (n = 3) represent the SE.
(D) HMS and HMR cells were treated with 3 mM bortezomib (B) or 3 mM MLN4924 (M) for the indicated times, and extracts were analyzed under nonreducing
conditions by immunoblotting for NEDD8. NEDD8-modified cullins, NEDD8-activated UBC12, andNEDD8 are indicated. a-Tubulin was used as a loading control.
See Figure S1 for immunoblotting for ubiquitin.
(E) The steady-state abundance of CRL substrates NRF2, p27, CDT1, cyclin E, and p21 and the cell death marker cleaved PARP (clPARP) were examined after
24 hr of treatment with the indicated concentration of MLN4924. GAPDH was used as a loading control.(Soucy et al., 2009), serially culturing them in the presence of
1 mM of the molecule over 4 weeks resulted in largely unaffected
cells. These cells, HMR (HCT116 MLN4924 resistant) cells,
proliferate similarly to untreated HCT116 cells (HMS cells,
HCT116 MLN4924 Sensitive) with doubling times of 17.1 and
16.6 hr, respectively (Figure 1A). Treatment of HMR cells with
3 mM MLN4924 slows this doubling time to 22.0 hr, indicating
a partial response to the molecule; however, this concentration
potently causes HMS cell death.
To quantitatively compare the sensitivity of HMS and HMR
cells to MLN4924, cell viability assays were performed with
increasing concentrations of themolecule (Figure 1B). HMS cells
are 20-fold less sensitive to MLN4924 than HMR cells
(MLN4924 EC50 values of 5.2 mM for HMR and 255 nM for
HMS). However, both are similarly sensitive to the proteasome
inhibitor bortezomib (EC50 6.6 and 8.0 nM, respectively), indi-
cating that HMR cells are not generally unresponsive to small
molecules.
The decreased sensitivity of HMR cells to MLN4924 could
arise through a variety of on- and off-target mechanisms that
singly or collectively confer resistance to cell death induced by310 Cell Reports 1, 309–316, April 19, 2012 ª2012 The Authorsthe molecule. To evaluate if the decreased sensitivity of HMR
cells to MLN4924 is due to impaired uptake or retention of
the compound or a decrease in its intracellular stability, the
steady-state levels of MLN4924 in HMS and HMR cells were
measured over time upon MLN4924 addition using liquid chro-
matography-tandem mass spectrometry (LC-MS/MS), and no
differences were detected (see Figure S1A). Additionally,
expression profiling did not identify changes in cytochrome
P450 superfamily genes (Figure S1B), which are often induced
in response to small molecules and are estimated to be respon-
sible for 75% of drug metabolism (Guengerich, 2008).
HMR Cells Maintain Neddylated Cullins
The effects of MLN4924 and bortezomib on the ubiquitin and
neddylation systems in HMR cells were evaluated by immuno-
blotting extracts for ubiquitin and NEDD8. Bortezomib treatment
(3 mM) resulted in the accumulation of high molecular weight pol-
yubiquitinated proteins with no differences between HMS and
HMR cells (Figure S1C). Immunoblotting these extracts for
NEDD8 under nonreducing conditions revealed that untreated
or bortezomib-treated HMR cells contain more monomeric
NEDD8 than HMS cells, and they also maintain activated UBC12
(UBC12NEDD8) in the presence of MLN4924 (Figure 1D). As
expected, MLN4924 treatment of HMS cells resulted in the rapid
loss of NEDD8-modified cullins. Although some decrease also
occurred in HMR cells, the steady-state levels of NEDD8-modi-
fied cullins persisted at levels higher than in HMS cells.
Collectively, these studies suggest that HMR cells are not
completely unresponsive to MLN4924 but are able to maintain
sufficient levels of NEDD8-modified cullins. To explore this
further, dose-response experiments were performed in which
HMS and HMR cells were treated for 48 hr with increasing
concentrations of MLN4924, and the steady-state levels of
several well-known CRL substrates were examined by immuno-
blot (Figure 1E). As expected, these substrates and the
apoptosis marker, cleaved PARP, all accumulated in HMS cells
in a dose-sensitive manner. In contrast, however, similar accu-
mulation was not observed in HMR cells. These observations
suggest that the levels of neddylated cullins maintained in the
presence of MLN4924 in HMR cells are sufficient to fulfill CRL
functions necessary to prevent cell death.
HMR Cells Contain a UBA3 Point Mutation
Our data are consistent with an alteration in the NEDD8 system
mediating decreased sensitivity of HMR cells to MLN4924.
Based on the mechanism of action of MLN4924 (Brownell
et al., 2010), we suspected that HMR cells contained a mutated
form of NAE. Because UBA3 contains the nucleotide binding
pocket that accommodates MLN4924 and the catalytic cysteine
necessary for formation of the inhibitory NEDD8-MLN4924 cova-
lent adduct (Figure 2A), this NAE subunit seemed a likely target
for mutations.
Sequencing of cloned UBA3 cDNAs from HMR cells identified
a single-point mutation at position 511 of theUBA3 open reading
frame in three out of six sequenced cDNAs distinct from those
of HMS cells (Figure S2A). This mutation occurs within the
coding sequence of the nucleotide binding pocket and repre-
sents a purine base transition from guanine (G) to adenine (A).
Sequencing of genomic DNA corresponding to this region deter-
mined thatHMRcells areheterozygousat this nucleotideposition
that results in either an alanine (A, thewild-type residue, encoded
by GCC codon) or threonine (T, generated by a nucleotide transi-
tion to ACC codon) encoded at position 171 within the UBA3
open reading frame (Figures 2BandS2B). Alanine 171 represents
a previously uncharacterized residuewithin UBA3 and is found at
a similar position in other canonical E1s (Figure 2C).
Molecular models of NAE with bound ATP and NEDD8 from
crystal structures (Figure 2D) suggest that the residue partici-
pates in defining an edge of the solvent-accessible nucleotide
binding pocket but does not directly contact ATP. The model
of NAE containing NEDD8-MLN4924 (Brownell et al., 2010)
indicates that this alanine side chain aligns parallel and in close
proximity to the aminoindane moiety of MLN4924 (Figure 2F).
Computer-simulated models of UBA3 containing A171T, in
contrast, suggest that A171T may not be compatible with
MLN4924 binding because this side chain has a steric clash
with the aminoindane (Figure 2G). Although it does not appear
to directly contact ATP (Figure 2E), the simulated A171T had
significant van der Waals overlaps with adjacent residues inUBA3. These suggest a mechanism of aminoindane-dependent
binding of MLN4924 through interactions with A171 and that
decreased sensitivity to MLN4924 may be conferred by A171T
inhibiting aminoindane-dependent MLN4924 binding. Moreover,
steric clashes observed in the simulated UBA3 A171T model
with ATP suggest that this mutation may alter the nucleotide
binding pocket.
UBA3 A171T Alters NAE Properties
To explore the effect of A171T on NAE activity, we generated re-
combinant NAE complexes containing either UBA3 or UBA3
A171T and examined these in ATP:PPi exchange experiments
(Bohnsack and Haas, 2003; Brownell et al., 2010; Bruzzese
et al., 2009). This assay measures the rate of radiolabeled ATP
formed from 32P-labeled PPi in a NAE- and NEDD8-dependent
manner, allowing for kinetic parameters of the enzyme in
NEDD8 activation to be directly extracted. In MLN4924 titration
experiments using ATP concentrations of either 100 mM (Fig-
ure 3A; raw data shown in Figure S3A) or 1 mM (Figures 3B
and S3B), NAE (UBA3 A171T) had an IC50 2-fold higher than
NAE (192 versus 63 nM, 100 mM ATP; 290 versus 170 nM,
1 mM ATP). These observations are consistent with A171T
reducing MLN4924 binding as expected from the modeling
described above. Moreover, the differences in IC50 values at
the two different ATP concentrations for both enzymes reflect
MLN4924’s function as an ATP-competitive inhibitor (Soucy
et al., 2009; Swords et al., 2010).
Notably, NAE (UBA3 A171T) had a consistently higher rate of
ATP synthesis than NAE at 1 mM ATP with a similar rate at
100 mM ATP. These observations suggest that the A171T muta-
tion also alters the nucleotide binding pocket to enhance
NEDD8 activation at high ATP concentrations. To explore this
hypothesis,we performed titration experimentswithATP (Figures
3C and S3C) and PPi (Figures 3D and S3D). Although NAE and
NAE (UBA3 A171T) had similar rates of ATP synthesis at low
concentrations of both ATP and PPi, higher concentrations of
either substrate resulted in increased rates forNAE (UBA3A171T).
Both titrations revealed 2-fold increases in the turnover
number kcat for NAE (UBA3 A171T), with 1.15 versus 0.52 s
1
for ATP and 0.79 versus 0.42 s1 for PPi compared to NAE.
We also measured a 4-fold increase in KM for ATP (1,006 mM
for NAE (UBA3 A171T) and 243 mM for NAE) with a minor effect
for PPi (4.2 and 3.5 mM). These studies suggest that UBA3
A171T decreases MLN4924 sensitivity by altering the nucleotide
binding pocket to reduce NAE’s affinity for both MLN4924 and
ATP. This mutation also results in correspondingly increased
rates of NEDD8 activation at high ATP concentrations. Interest-
ingly, intracellular ATP is typically at 1–10 mM (Beis and News-
holme, 1975), close to the measured KM of NAE (UBA3 A171T).
UBA3 A171T Confers MLN4924 Resistance
Because HMR cells are heterozygous for this mutation in the
UBA3 gene, UBA3 A171T should provide a dominant effect on
NAE functions to allow cell survival in the presence of
MLN4924. To test this hypothesis, HCT116 cells were trans-
fected with plasmids to express either UBA3 (WT) or UBA3
A171T and were treated with either DMSO (MLN4924) or
3 mM MLN4924 for 72 hr. Although cells transfected with eitherCell Reports 1, 309–316, April 19, 2012 ª2012 The Authors 311
Figure 2. HMR Cells Are Heterozygous for a Single-Nucleotide Transition within the Coding Sequence of the UBA3 Nucleotide Binding
Pocket
(A) Domain structure of NAE subunits, UBA3 (UBE1C) and NAE1 (ULA1, APPBP1).
(B) Chromatograms from sequencing reactions analyzing genomic DNA from HMS and HMR cells determined that HMR cells are heterozygous for a G to A
transition (indicated by arrow) that alters an amino acid within the UBA3 nucleotide binding pocket. This transition results in the conversion of alanine 171 to
threonine (A171T) in the UBA3 open reading frame. See Figure S2 for sequences of cDNAs and extended genomic DNA sequence.
(C–G) A sequence alignment of canonical E1s indicates similarly positioned alanine residues (indicated by arrow) found in other E1s (C). The catalytic cysteines
are highlighted in yellow.Molecular models of the NAE nucleotide binding pocket with ATP bound to UBA3 (D) or UBA3 A171T (E) andMLN4924-NEDD8 bound to
UBA3 (F) or UBA3 A171T (G). The solvent-accessible nucleotide binding pocket is indicated as are side chains important for MLN4924 binding. Dot-surface
representation for A171 and computer-modeled A171T is shown with only the rotamer with the highest frequency of occurrence in proteins. Computer-modeled
A171T rotamers in (E) had significant van der Waals overlaps with other residues in UBA3, suggesting that it could alter the nucleotide binding pocket. Inter-
estingly, the two major A171T rotamers modeled in (G) had significant van der Waals overlap with the aminoindane of MLN4924, but only minor contacts with
other UBA3 residues. These models are based on PDB accession codes 1R4N (D and E) and 3GZN (F and G).vector or UBA3 did not survive MLN4924 treatment, those ex-
pressing UBA3 A171T did (Figure 4A). This effect is not attribut-
able to UBA3 overexpression because both transfected forms
were expressed similarly and at levels comparable to the endog-
enous UBA3 isoforms detected by immunoblot (Figure 4B).312 Cell Reports 1, 309–316, April 19, 2012 ª2012 The AuthorsTo compare the effects of transient UBA3 A171T expression
in HCT116 cells to HMS and HMR cells, viability assays were
performed with increasing MLN4924 concentrations (Figure 4C).
The measured EC50 for HCT116 cells expressing UBA3
A171T was 3.2 mM, which is near the 7.8 mM for HMR cells and
Figure 3. NAE (UBA3 A171T) Is Less Sensitive to MLN4924 and Activates NEDD8 More Efficiently In Vitro
MLN4924 titrations (2-fold dilutions) in NAE ATP:PPi exchange assay using 100 mMATP (A) or 1 mMATP (B). Kinetic measurements of ATP:PPi exchange by NAE
and NAE (UBA3 A171T) in ATP (C) and PPi (D) titrations. ATP titrations used 1mMPPi with the indicated concentrations of ATP. PPi titrations used 2mMATPwith
the indicated concentrations of PPi. All reactions included 50 cpm/pmol of [32P]PPi, 100 mM NEDD8, and 10 nM of NAE or NAE (A171T), and were incubated at
37C for 30 min. See Figure S3 for raw data. Error bars (n = 3) represent the SE.15-fold higher than the 215 nM EC50 for HMS cells. Thus, UBA3
A171T confers MLN4924 resistance to HCT116 cells. Moreover,
the underlying single-nucleotide transition is sufficient for
increased cell survival in the presence of the molecule.
DISCUSSION
We have identified a point mutation in UBA3 that causes
decreased sensitivity to the NAE inhibitor MLN4924. This muta-
tion arises through on-target selective pressure and alters the
UBA3 nucleotide binding pocket such that MLN4924 binding is
impaired through a reduction in the enzyme’s affinity for both
ATP and MLN4924. This effectively decreases MLN4924’s func-
tion as an ATP competitive inhibitor because the cellular concen-
tration of ATP is in the millimolar range (Beis and Newsholme,
1975)— near the KM for NAE (UBA3 A171T). Additionally, cancer
cells typically have elevated ATP levels through increases in
aerobic respiration via the Warburg effect (Warburg, 1956).
These collectively support sufficient levels of essential NEDD8-
dependent CRL functions in the presence of MLN4924 concen-
trations that typically induce cancer cell death.
In vitro approaches similar to the one described here have
successfully identified clinical-resistance mechanisms to cancer
therapeutics such as the BCR-ABL inhibitor imatinib (Gleevec)
and the epidermal growth factor receptor (EGFR) inhibitors gefi-tinib (Iressa), and erlotinib (Tarceva) (Bell et al., 2005; Cools et al.,
2003; Kobayashi et al., 2005; Pao et al., 2005; Shah et al., 2002,
2004; Tamborini et al., 2004, 2006; von Bubnoff et al., 2005).
EGFR and BCR-ABL contain a ‘‘gatekeeper’’ residue that
controls inhibitor access to the ATP binding site while not directly
contacting ATP. Mutation of the gatekeeper residue to one that
prevents inhibitor binding is a major mechanism of clinical resis-
tance in patients undergoing treatment with EGFR andBCR-ABL
inhibitors. The observation that A171 comes in close proximity
to the aminoindane of MLN4924 (Figure 2F) while not contacting
ATP (Figure 2D) suggests that it functions in a similar gatekeeper
role. It will be interesting to see if mutation of this residue plays
a role in clinical resistance to MLN4924 therapy. Conservation
of this residue in other canonical E1s (Figure 2C) and the
mechanism of action of aminoindane-containing E1 inhibitors
(Brownell et al., 2010; Chen et al., 2011) suggest that this alanine
may play a more general role as a gatekeeper residue for aden-
osine sulfamate-based E1 inhibitors.
EXPERIMENTAL PROCEDURES
MLN4924 Synthesis
A detailed description of the synthesis is described in Extended Experimental
Procedures. Purity and characterization of intermediate compounds and
MLN4924 were established by a combination of liquid chromatography-
mass spectroscopy (LC-MS) and analytical NMR.Cell Reports 1, 309–316, April 19, 2012 ª2012 The Authors 313
Figure 4. Expression of UBA3A171T Is Sufficient toConferMLN4924
Resistance
(A) HCT116 cells transfected with the indicated plasmids were either treated
with DMSO (MLN4924) or 3 mM MLN4924 for 72 hr prior to crystal violet
staining.
(B) The expression of FLAG-tagged UBA3 was examined by immunoblot of
UBA3 and FLAG in transfected HCT116 cells. GAPDH was used as a loading
control.
(C) Expression of UBA3 A171T increases HCT116 cell survival in the presence
of increasing concentrations of MLN4924. Cell viability measurements for
HMS and HMR cells treated with MLN4924 are shown for comparison. Error
bars (n = 3) represent the SE.Isolation of MLN4924-Resistant HCT116 Cells
HCT116 cells (2 3 105; ATCC) were incubated in 1 mM MLN4924 with
the media containing the compound changed every 48 hr. After 17 days,
the MLN4924 concentration was increased to 1.5 mM, followed by 2 mM at
day 21 and 3 mM at day 25. These HMR cells were maintained in 3 mM
MLN4924.
Cell Proliferation and Viability Assays
HMR and HMS cells (105 cells) were incubated in DMSO (0.1% final
concentration) or 3 mM MLN4924. After 24, 48, and 72 hr, cells were counted
using a TC10 Automated Cell Counter (Bio-Rad). Culture media were
replenished every 24 hr. Cell numbers represent the mean (n = 3) with error
bars representing SE. See Extended Experimental Procedures for additional
details.
For viability measurements, cells were plated at 4,000 cells per well, and
media were added containing 3-fold serial dilutions of MLN4924 from
a maximum of 20 mM or bortezomib from 2 mM after 24 hr. After 48 hr, ATP
content was measured using Cell Titer-Glo Luminescent Viability Assay
(Promega). Extended Experimental Procedures describe analysis methods.314 Cell Reports 1, 309–316, April 19, 2012 ª2012 The AuthorsProtein Expression Analyses
Cells (2.8 3 106 for 24 hr treatments or 5 3 106 for 60 min time course exper-
iments) were incubated with DMSO or MLN4924 (0.03–3 mM for 24 hr treat-
ments, 3 mM for time courses) after 24 hr. At the indicated times, cells were
washed and scraped into cold PBS and resuspended in 25 mM HEPES
(pH 7.6), 300 mM NaCl, 0.2% Triton X-100, 2 mM EDTA, 5 mM MgCl2, 5 mM
1,10-phenanthroline, 1 mM iodoacetamide, and Halt protease inhibitor
cocktail (Thermo Scientific). Protein concentrations were determined by
Bradford assay prior to analysis of equivalent lysate amounts by SDS-PAGE
and immunoblotting. Antibodies used are described in Extended Experimental
Procedures.
Molecular Models
All models were rendered in PyMOL (Schro¨dinger) and used publicly available
data from the Protein Data Bank (PDB): 1R4N (Walden et al., 2003) and 3GZN
(Brownell et al., 2010). The solvent-accessible nucleotide binding pocket
(rendered using three solvent radii for cavity detection and one solvent radius
for cavity detection cutoff) and side chains of UBA3 important for MLN4924
binding to NAE are shown. Computer modeling of A171T in NAE was
performed using the PyMOL mutagenesis algorithm in which backbone-
dependent rotamers of threonine were examined. Only the rotamer with the
highest frequency of occurrence in proteins is shown.
Recombinant NAE and NEDD8
ULA1, UBA3, and UBA3 A171T (isoform 1), and NEDD8 open reading frames
were prepared as baculoviruses for insect cell expression (ULA1, UBA3, UBA3
A171T) or for E. coli expression (NEDD8). NAE complexes were purified by
Ni-NTA chromatography from coinfecting Hi5 cultures (106 cells/ml, 100 ml)
with viruses to express ULA1 and hexahistidine-tagged UBA3 or UBA3
A171T for 48 hr. NEDD8 was expressed in Rosetta 2 E. coli (Novagen) and
purified by SP Sepharose chromatography. Protein concentrations were
measured from Coomassie-stained gels scanned on a Li-Cor Odyssey, using
known amounts of purified BSA to generate a standard curve and the
instrument’s analysis software.
ATP:PPi Exchange Assay
The assay is based on a published method (Brownell et al., 2010; Bruzzese
et al., 2009). Experiments were performed such that NAE or NAE (UBA3
A171T) was premixed with titrants (MLN4924, ATP, or PPi) and other assay
components, including 50 cpm/pmol [32P]PPi. Reactions (50 ml final volume
in 25 mM HEPES [pH 7.6], 5 mM MgCl2, 25 mM NaCl, 0.5 mM DTT, and using
NAE and NAE (UBA3 A171T) at 10 nM) were initiated by the addition of NEDD8
to 1 mM, incubated at 37C for 30 min, and terminated with 400 ml 5% TCA,
10mMPPi. Reactionswere transferred to activated charcoal paper by vacuum
filtration with each washed four times with 250 ml 2% TCA, 10 mM PPi, and
the filter washed five times with 100 ml over 25 min. The filter was exposed
to a phosphor screen and imaged on a Fuji FLA-5100. Resulting signals
representing NAE-generated radiolabeled ATP were quantified using Multi
Gauge software and ATP standards. All measurements are shown as the
mean (n = 3) with error bars representing the SEM. Raw data are shown in Fig-
ure S3 as well as descriptions of additional experimental details. Data analyses
used GraphPad Prism software and a nonlinear regression algorithm to
measure kcat and extract other best-fit values from plots of rates of ATP
synthesis versus substrate concentration.
Transient UBA3 Expression
Plasmids expressing FLAG-tagged UBA3 and UBA3 A171T from the CMV
promoter were transfected into HCT116 cells using Lipofectamine 2000
(Invitrogen). After 24 hr, protein extracts from a portion of the cells were
normalized as described above and immunoblotted for UBA3, FLAG-M2
(Sigma; F1804), and GAPDH. The remaining cells were plated at 4 3 105 in
a 6-well plate. After another 24 hr, 0.1% DMSO or 3 mMMLN4924 was added
and incubated for 72 hr prior to staining with 1% crystal violet in 10% ethanol.
Cell viability assays were performed as described above except cells were first
transferred to a 10 cm2 plate 24 hr post-transfection and treated for 48 hr with
3 mM MLN4924 prior to seeding into a 96-well plate.
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